Results 161 to 170 of about 26,368 (251)

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study. [PDF]

Cancer Commun (Lond)
Li H, Chen M, Huang R, Rong Q, Hao J, Zheng Q, Su Y, Shu D, Zhang Y, Yang W, Lei X, Cai Y, Xue C, An X, Shi Y.   +14 more
europepmc   +1 more source

nab-paclitaxel/carboplatin induction in squamous NSCLC: Longitudinal quality of life while on chemotherapy [PDF]

, 2017
et al,, Morgensztern, Daniel
core   +1 more source

Neoadjuvant nab-paclitaxel in the treatment of breast cancer [PDF]

, 2016
Eleftherios P. Mamounas, Naoto T. Ueno
core   +1 more source

Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study [PDF]

, 2016

core   +1 more source

NSCLC: Verträglichere Therapie mit nab-Paclitaxel [PDF]

Im Focus Onkologie, 2015
openaire   +1 more source

Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress. [PDF]

Pleura Peritoneum
Popat V, Frankel PH, Ruel NH, Yost SE, Chang S, Wang E, Villella J, Whyte J, Whelan RL, Eng M, Tinsley R, Synold T, Han E, Song M, Cohen J, Raoof M, Dellinger TH.   +16 more
europepmc   +1 more source

Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer. [PDF]

Cancer Med
Wang Y, Zhang WJ, Lu YX, Liu SL, Zhang ZY, Zhang SM, Wang TW, Zhong Y, Zhang DS.   +8 more
europepmc   +1 more source

Efficacy and safety of nab-paclitaxel plus PD-1 inhibitor in elderly patients with advanced squamous lung cancer. [PDF]

BMC Cancer
Qian H, Jiang J, Li S, Ni C, Chen Y, Song Y, Zhu T, Yan Y.   +7 more
europepmc   +1 more source

Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer: A Systematic Review. [PDF]

Cancer Med
Sohrabi H, Ghavam SM, Azadnajafabad S, Rezaei N.   +3 more
europepmc   +1 more source

Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights. [PDF]

Am J Cancer Res
Merc Cetınkaya A, Tatlı AM, Goktas Aydın S, Kılıckap S, Bılıcı A, Bırıcık FS, Kostek O, Kayıkcıoglu E, Paydas S, Artac M, Teker F, Cıl T, Kaplan MA, Hacıbekıroglu İ, Geredelı C, Bayram E, Altıntas YE, Celebı AS, Kocak MZ, Arak H, Arslan Benlı B, Arvas H, Dınc Sonusen S, Sezgın Goksu S.   +23 more
europepmc   +1 more source